Is prolactin involved in the evolution of atherothrombotic disease?

Expert Review of Endocrinology and Metabolism

Volumn 7, Issue 3, 2012, Pages 345-361

  Reuwer, Anne Q ^a,b   Hoekstra, Menno ^c   Touraine, Philippe ^d,e,f   Twickler, Marcel Thb ^a,g   Goffin, Vincent ^f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Tergooiziekenhuizen ^*  (Netherlands)

^c LEIDEN UNIVERSITY   (Netherlands)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e SORBONNE UNIVERSITÉ   (France)

^f INSERM   (France)

^g ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

atherothrombosis; inflammation; metabolic syndrome; prolactin receptor antagonists; prolactin lowering therapy; prolactinoma; residual cardiovascular risk

Indexed keywords

ALDOSTERONE; C REACTIVE PROTEIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERLEUKIN 12P40; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; NORADRENALIN; PROLACTIN; PROLACTIN RECEPTOR; PROTHROMBIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; TYROSINE; VERY LOW DENSITY LIPOPROTEIN;

ARTERIAL WALL THICKNESS; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE; BODY MASS; CANCER PATIENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CYTOKINE PRODUCTION; DISEASE COURSE; FIBRINOLYSIS; HUMAN; HYPERTENSION; IMMUNOCOMPETENT CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; NONHUMAN; PRIORITY JOURNAL; PROLACTINOMA; PROTEIN PHOSPHORYLATION; PULSE WAVE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIGNAL TRANSDUCTION; THROMBOSIS;

EID: 84862109213     PISSN: 17446651     EISSN: 17448417     Source Type: Journal    
DOI: 10.1586/eem.12.23     Document Type: Review

References (109)

1. Kizer JR, Madias C, Wilner B et al. Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am. J. Cardiol. 105 (9), 1289-1296 (2010).
2. Baigent C, Blackwell L, Emberson J et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000participants in 26 randomised trials. Lancet 376 (9753), 1670-1681 (2010).
3. Ray KK, Seshasai SR, Erqou S et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. Arch. Intern. Med. 170 (12), 1024-1031 (2010).
4. van Zaane B, Reuwer AQ, Büller HR, Kastelein JJ, Gerdes VE, Twickler MT. Hormones and cardiovascular disease:a shift in paradigm with clinical consequences? Semin. Thromb. Hemost. 35 (5), 478-487 (2009).
5. Schultz M, Kistorp C, Raymond I et al. Cardiovascular events in thyroid disease: a population based, prospective study. Horm. Metab. Res. 43 (9), 653-659 (2011).
6. Rodondi N, Newman AB, Vittinghoff E et al. Subclinical hypothyroidism and the risk of heart failure, other cardiovascular events, and death. Arch. Intern. Med. 165 (21), 2460-2466 (2005). (Pubitemid 41720006)
7. Biondi B, Palmieri EA, Lombardi G, Fazio S. Effects of subclinical thyroid dysfunction on the heart. Ann. Intern. Med. 137 (11), 904-914 (2002). (Pubitemid 35416626)
8. Corona G, Rastrelli G, Vignozzi L, Mannucci E, Maggi M. Testosterone, cardiovascular disease and the metabolic syndrome. Best Pract. Res. Clin. Endocrinol. Metab. 25 (2), 337-353 (2011).
9. Cachofeiro V, Miana M, de Las Heras N et al. Aldosterone and the vascular system. J. Steroid Biochem. Mol. Biol. 109 (3-5), 331-335 (2008).
10. Corona G, Rastrelli G, Balercia G, Sforza A, Forti G, Maggi M. Testosterone and cardiovascular risk in patients with erectile dysfunction. J. Endocrinol. Invest. (2011) (Epub ahead of print).
11. Araujo AB, Wittert GA. Endocrinology of the aging male. Best Pract. Res. Clin. Endocrinol. Metab. 25 (2), 303-319 (2011).
12. Ruidavets JB, Luc G, Machez E et al. Effects of insulin-like growth factor 1 in preventing acute coronary syndromes: the PRIME study. Atherosclerosis 218 (2), 464-469 (2011).
13. Shai SY, Sukhanov S, Higashi Y, Vaughn C, Rosen CJ, Delafontaine P. Low circulating insulin-like growth factor I increases atherosclerosis in apoE-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 300 (5), H1898-H1906 (2011).
14. von der Thüsen JH, Borensztajn KS, Moimas S et al. IGF-1 has plaquestabilizing effects in atherosclerosis by altering vascular smooth muscle cell phenotype. Am. J. Pathol. 178 (2), 924-934 (2011).
15. Silva JE, Bianco SD. Thyroid-adrenergic interactions: physiological and clinical implications. Thyroid 18 (2), 157-165 (2008). (Pubitemid 351271529)
16. Riddle O, Bates RW, Dykshorn SW. The preparation, identification and assay of prolactin-a hormone of the anterior pituitary. Am. J. Physiol. 105, 191-216 (1933).
17. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol. Rev. 80 (4), 1523-1631 (2000).
18. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr. Rev. 17 (6), 639-669 (1996). (Pubitemid 26425260)
19. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr. Rev. 24 (1), 1-27 (2003). (Pubitemid 36223277)
20. Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Nat. Rev. Urol. 8 (11), 597-607 (2011).
21. Horseman ND, Zhao W, Montecino-Rodriguez E et al. Defective mammopoiesis, but normal hematopoiesis, in mice with a targeted disruption of the prolactin gene. EMBO J. 16 (23), 6926-6935 (1997). (Pubitemid 27520793)
22. Ormandy CJ, Camus A, Barra J et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev. 11 (2), 167-178 (1997). (Pubitemid 27081894)
23. Pullano JG, Cohen-Addad N, Apuzzio JJ, Ganesh VL, Josimovich JB. Water and salt conservation in the human fetus and newborn. I. Evidence for a role of fetal prolactin. J. Clin. Endocrinol. Metab. 69 (6), 1180-1186 (1989). (Pubitemid 20010045)
24. Berl T, Brautbar N, Ben-David M, Czaczkes W, Kleeman C. Osmotic control of prolactin release and its effect on renal water excretion in man. Kidney Int. 10 (2), 158-163 (1976).
25. Clément-Lacroix P, Ormandy C, Lepescheux L et al. Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 140 (1), 96-105 (1999). (Pubitemid 29011146)
26. Brandebourg T, Hugo E, Ben-Jonathan N. Adipocyte prolactin: regulation of release and putative functions. Diabetes Obes. Metab. 9 (4), 464-476 (2007). (Pubitemid 47018509)
27. Viengchareun S, Servel N, Fève B, Freemark M, Lombès M, Binart N. Prolactin receptor signaling is essential for perinatal brown adipocyte function: a role for insulin-like growth factor-2. PLoS ONE 3 (2), e1535 (2008).
28. Molinari C, Grossini E, Mary DA et al. Prolactin induces regional vasoconstriction through the beta2-adrenergic and nitric oxide mechanisms. Endocrinology 148 (8), 4080-4090 (2007). (Pubitemid 47105845)
29. Sauro MD, Zorn NE. Prolactin induces proliferation of vascular smooth muscle cells through a protein kinase C-dependent mechanism. J. Cell. Physiol. 148 (1), 133-138 (1991). (Pubitemid 21910135)
30. Karnik SK, Chen H, McLean GW et al. Menin controls growth of pancreatic beta-cells in pregnant mice and promotes gestational diabetes mellitus. Science 318 (5851), 806-809 (2007). (Pubitemid 351411773)
31. Langan EA, Ramot Y, Goffin V, Griffiths CE, Foitzik K, Paus R. Mind the (gender) gap: does prolactin exert gender and/or site-specific effects on the human hair follicle? J. Invest. Dermatol. 130 (3), 886-891 (2010).
32. Dorshkind K, Horseman ND. The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency. Endocr. Rev. 21 (3), 292-312 (2000). (Pubitemid 32275590)
33. Bouchard B, Ormandy CJ, Di Santo JP, Kelly PA. Immune system development and function in prolactin receptordeficient mice. J. Immunol. 163 (2), 576-582 (1999). (Pubitemid 29328058)
34. Bole-Feysot C, Goffin V, Edery M, Binart N, Kelly PA. Prolactin (PRL) and its receptor: actions, signal transduction pathways and phenotypes observed in PRL receptor knockout mice. Endocr. Rev. 19 (3), 225-268 (1998). (Pubitemid 29117815)
35. Ben-Jonathan N, LaPensee CR, LaPensee EW. What can we learn from rodents about prolactin in humans? Endocr. Rev. 29 (1), 1-41 (2008). (Pubitemid 351252745)
36. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 145 (3), 341-355 (2011).
37. Williams KJ, Tabas I. The response-toretention hypothesis of early atherogenesis. Arterioscler. Thromb. Vasc. Biol. 15 (5), 551-561 (1995).
38. Glass CK, Witztum JL. Atherosclerosis. the road ahead. Cell 104 (4), 503-516 (2001).
39. Gibbons GF. Assembly and secretion of hepatic very-low-density lipoprotein. Biochem. J. 268 (1), 1-13 (1990). (Pubitemid 20166643)
40. Spring DJ, Chen-Liu LW, Chatterton JE, Elovson J, Schumaker VN. Lipoprotein assembly. Apolipoprotein B size determines lipoprotein core circumference. J. Biol. Chem. 267 (21), 14839-14845 (1992).
41. Montes de Oca P, Macotela Y, Nava G, López-Barrera F, de la Escalera GM, Clapp C. Prolactin stimulates integrin-mediated adhesion of circulating mononuclear cells to endothelial cells. Lab. Invest. 85 (5), 633-642 (2005). (Pubitemid 40675444)
42. Paulson KE, Zhu SN, Chen M, Nurmohamed S, Jongstra-Bilen J, Cybulsky MI. Resident intimal dendritic cells accumulate lipid and contribute to the initiation of atherosclerosis. Circ. Res. 106 (2), 383-390 (2010).
43. Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J. Lipid Res. 50 (Suppl.), S382-S387 (2009).
44. Lusis AJ. Atherosclerosis. Nature 407 (6801), 233-241 (2000).
45. Schuett H, Luchtefeld M, Grothusen C, Grote K, Schieffer B. How much is too much? Interleukin-6 and its signalling in atherosclerosis. Thromb. Haemost. 102 (2), 215-222 (2009).
46. Tripathi A, Sodhi A. Production of nitric oxide by murine peritoneal macrophages in vitro on treatment with prolactin and growth hormone: involvement of protein tyrosine kinases, Ca (++), and MAP kinase signal transduction pathways. Mol. Immunol. 44 (12), 3185-3194 (2007). (Pubitemid 46610507)
47. Sodhi A, Tripathi A. Prolactin and growth hormone induce differential cytokine and chemokine profile in murine peritoneal macrophages in vitro: involvement of p-38 MAP kinase, STAT3 and NF-kappaB. Cytokine 41 (2), 162-173 (2008).
48. Zellweger R, Zhu XH, Wichmann MW, Ayala A, DeMaso CM, Chaudry IH. Prolactin administration following hemorrhagic shock improves macrophage cytokine release capacity and decreases mortality from subsequent sepsis. J. Immunol. 157 (12), 5748-5754 (1996). (Pubitemid 126449000)
49. Ranjbaran H, Sokol SI, Gallo A et al. An inflammatory pathway of IFN-gamma production in coronary atherosclerosis. J. Immunol. 178 (1), 592-604 (2007). (Pubitemid 46033643)
50. Matera L, Mori M. Cooperation of pituitary hormone prolactin with interleukin-2 and interleukin-12 on production of interferon-gamma by natural killer and T cells. Ann. NY Acad. Sci. 917,505-513 (2000).
51. Yang L, Hu Y, Li X, Zhao J, Hou Y. Prolactin modulates the functions of murine spleen CD11C-positive dendritic cells. Int. Immunopharmacol. 6 (9), 1478-1486 (2006). (Pubitemid 44056290)
52. Matera L, Galetto A, Geuna M et al. Individual and combined effect of granulocyte-macrophage colonystimulating factor and prolactin on maturation of dendritic cells from blood monocytes under serum-free conditions. Immunology 100 (1), 29-36 (2000). (Pubitemid 30242879)
53. Horseman ND, Yu-Lee LY. Transcriptional regulation by the helix bundle peptide hormones: growth hormone, prolactin, and hematopoietic cytokines. Endocr. Rev. 15 (5), 627-649 (1994). (Pubitemid 24328209)
54. Tabas I, Tall A, Accili D. The impact of macrophage insulin resistance on advanced atherosclerotic plaque progression. Circ. Res. 106 (1), 58-67 (2010).
55. Vorchheimer DA, Becker R. Platelets in atherothrombosis. Mayo Clin. Proc. 81 (1), 59-68 (2006). (Pubitemid 43054319)
56. Atmaca A, Gurlek A, Dagdelen S et al. Hyperprolactinemia of pregnancy is not associated with increased in vivo platelet activity and shortened in vitro bleeding times. Exp. Clin. Endocrinol. Diabetes 114 (4), 188-191 (2006). (Pubitemid 43845196)
57. Wallaschofski H, Donné M, Eigenthaler M et al. PRL as a novel potent cofactor for platelet aggregation. J. Clin. Endocrinol. Metab. 86 (12), 5912-5919 (2001). (Pubitemid 33152644)
58. Reuwer AQ, Nieuwland R, Fernandez I et al. Prolactin does not affect human platelet aggregation or secretion. Thromb. Haemost. 101 (6), 1119-1127 (2009).
59. Reuwer AQ, Sondermeijer BM, Battjes S et al. Microcirculation and atherothrombotic parameters in prolactinoma patients: a pilot study. Pituitary doi:10.1007/s11102-011-0353-9 (2011) (Epub ahead of print).
60. Nishino Y. Hormonal control of prothrombin synthesis in rat liver microsomes, with special reference to the role of estradiol, testosterone and prolactin. Arch. Toxicol. 2, 397-402 (1979). (Pubitemid 9179391)
61. Houlihan CM, Knuppel RA, Vintzileos AM, Guo JZ, Hahn DW. The effect of specific hormones on fibrinolysis in pregnancy. Am. J. Obstet. Gynecol. 175 (1), 168-172 (1996). (Pubitemid 26282225)
62. Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O. Blood coagulation, fibrinolysis and lipid profile in patients with prolactinoma. Clin. Endocrinol. 73 (4), 502-507 (2010).
63. Reuwer AQ, van Eijk M, Houttuijn-Bloemendaal FM et al. The prolactin receptor is expressed in macrophages within human carotid atherosclerotic plaques: a role for prolactin in atherogenesis? J. Endocrinol. 208 (2), 107-117 (2011).
64. Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab. 91 (12), 4769-4775 (2006). (Pubitemid 44917305)
65. Raappana A, Koivukangas J, Ebeling T, Pirilä T. Incidence of pituitary adenomas in Northern Finland in 1992-2007. J. Clin. Endocrinol. Metab. 95 (9), 4268-4275 (2010).
66. Colao A, Lombardi G. Growth-hormone and prolactin excess. Lancet 352 (9138), 1455-1461 (1998). (Pubitemid 28510890)
67. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 24 (4), 683-689 (2001). (Pubitemid 32893993)
68. Lakka HM, Laaksonen DE, Lakka TA et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (21), 2709-2716 (2002). (Pubitemid 35403784)
69. Mathieu P, Pibarot P, Després JP. Metabolic syndrome: the danger signal in atherosclerosis. Vasc. Health Risk Manag. 2 (3), 285-302 (2006). (Pubitemid 44275464)
70. Ross R, Després JP. Abdominal obesity, insulin resistance, and the metabolic syndrome: contribution of physical activity/exercise. Obesity 17(Suppl. 3), S1-S2 (2009).
71. Berinder K, Nyström T, Höybye C, Hall K, Hulting AL. Insulin sensitivity and lipid profile in prolactinoma patients before and after normalization of prolactin by dopamine agonist therapy. Pituitary 14 (3), 199-207 (2011).
72. dos Santos Silva CM, Barbosa FR, Lima GA et al. BMI and metabolic profile in patients with prolactinoma before and after treatment with dopamine agonists. Obesity 19 (4), 800-805 (2011).
73. Pelkonen R, Nikkilä EA, Grahne B. Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin. Endocrinol. 16 (4), 383-390 (1982). (Pubitemid 12188630)
74. Serri O, Li L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G. The influences of hyperprolactinemia andobesity on cardiovascular risk markers: effects of cabergoline therapy. Clin. Endocrinol. 64 (4), 366-370 (2006).
75. Yavuz D, Deyneli O, Akpinar I et al. Endothelial function, insulin sensitivity and inflammatory markers in hyperprolactinemic pre-menopausal women. Eur. J. Endocrinol. 149 (3), 187-193 (2003). (Pubitemid 37120990)
76. Ridker PM, MacFadyen J, Libby P, Glynn RJ. Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am. J. Cardiol. 106 (2), 204-209 (2010).
77. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 26 (3), 400-422 (2005). (Pubitemid 40686651)
78. Doknic M, Pekic S, Zarkovic M et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur. J. Endocrinol. 147 (1), 77-84 (2002). (Pubitemid 34814743)
79. Greenman Y, Tordjman K, Stern N. Increased body weight associated with prolactin secreting pituitary adenomas: weight loss with normalization of prolactin levels. Clin. Endocrinol. 48 (5), 547-553 (1998). (Pubitemid 28252990)
80. Freemark M, Avril I, Fleenor D et al. Targeted deletion of the PRL receptor: effects on islet development, insulin production, and glucose tolerance. Endocrinology 143 (4), 1378-1385 (2002). (Pubitemid 34274368)
81. Flint DJ, Clegg RA, Vernon RG. Prolactin and the regulation of adipose-tissue metabolism during lactation in rats. Mol. Cell. Endocrinol. 22 (2), 265-275 (1981). (Pubitemid 11109011)
82. de Moura EG, Bonomo IT, Nogueira-Neto JF et al. Maternal prolactin inhibition during lactation programs for metabolic syndrome in adult progeny. J. Physiol. (Lond.) 587 (Pt 20), 4919-4929 (2009).
83. Corona G, Mannucci E, Jannini EA et al. Hypoprolactinemia: a new clinical syndrome in patients with sexual dysfunction. J. Sex. Med. 6 (5), 1457-1466 (2009).
84. Muldoon MF, Mackey RH, Williams KV, Korytkowski MT, Flory JD, Manuck SB. Low central nervous system serotonergic responsivity is associated with the metabolic syndrome and physical inactivity. J. Clin. Endocrinol. Metab. 89 (1), 266-271 (2004). (Pubitemid 38183892)
85. Muldoon MF, Mackey RH, Korytkowski MT, Flory JD, Pollock BG, Manuck SB. The metabolic syndrome is associated with reduced central serotonergic responsivity in healthy community volunteers. J. Clin. Endocrinol. Metab. 91 (2), 718-721 (2006). (Pubitemid 43236948)
86. Wong TY, Klein R, Couper DJ et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet 358 (9288), 1134-1140 (2001). (Pubitemid 32971846)
87. Mitchell P, Wang JJ, Wong TY, Smith W, Klein R, Leeder SR. Retinal microvascular signs and risk of stroke and stroke mortality. Neurology 65 (7), 1005-1009 (2005). (Pubitemid 41429622)
88. Borissoff JI, Spronk HM, ten Cate H. The hemostatic system as a modulator of atherosclerosis. N. Engl. J. Med. 364 (18), 1746-1760 (2011).
89. Reuwer AQ, van Zaane B, van Wissen M, van Zanten AP, Twickler MT, Gerdes VE. Prolactin is involved in the systemic inflammatory response in myocardial infarction. Horm. Metab. Res. 43 (1), 62-65 (2011).
90. Raaz D, Wallaschofski H, Stumpf C et al. Increased prolactin in acute coronary syndromes as putative co-activator of ADP-stimulated P-selectin expression. Horm. Metab. Res. 38 (11), 767-772 (2006). (Pubitemid 44885431)
91. Gordon EM, Hellerstein HK, Ratnoff OD, Arafah BM, Yamashita TS. Augmented Hageman factor and prolactin titers, enhanced cold activation of Factor VII, and spontaneous shortening of prothrombin time in survivors of myocardial infarction. J. Lab. Clin. Med. 109 (4), 409-413 (1987). (Pubitemid 17064442)
92. Ferrari R, Ceconi C, Rodella A, Harris P, Visioli O. Hormonal response in untreated myocardial infarction. Cardioscience 1 (1), 55-60 (1990). (Pubitemid 20375437)
93. Horrobin DF, McNeilly AS, Jackson FS et al. Letter: prolactin and myocardial infarction. Lancet 2 (7840), 1261 (1973).
94. Weizman R, Eldar M, Hod H et al. Effects of uncomplicated acute myocardial infarction on biochemical parameters of stress and sexual function. Psychosomatics 32 (3), 275-279 (1991).
95. La Follette L, Gordon EM, Mazur CA, Ratnoff OD, Yamashita TS. Hyperprolactinemia and reduction in plasma titers of Hageman factor, prekallikrein, and high molecular weight kininogen in patients with acute myocardial infarction. J. Lab. Clin. Med. 110 (3), 318-321 (1987). (Pubitemid 18021155)
96. Ben-Jonathan N, Hugo ER, Brandebourg TD, LaPensee CR. Focus on prolactin as a metabolic hormone. Trends Endocrinol. Metab. 17 (3), 110-116 (2006).
97. Georgiopoulos GA, Stamatelopoulos KS, Lambrinoudaki I et al. Prolactin and preclinical atherosclerosis in menopausal women with cardiovascular risk factors. Hypertension 54 (1), 98-105 (2009).
98. Carrero JJ, Kyriazis J, Sonmez A et al. Prolactin levels, endothelial dysfunction, and the risk of cardiovascular events and mortality in patients with CKD. Clin. J. Am. Soc. Nephrol. 7 (2), 207-215 (2012).
99. Mediskou P, Yavropoulou MP, Kotsa K et al. The renin-angiotensin- aldosterone axis in patients with nontumoral [corrected] hyperprolactinemia. Clin. Endocrinol. 74 (3), 306-311 (2011).
100. Degli Esposti E, Sturani A, Santoro A, Zuccalà A, Chiarini C, Zucchelli P. Effect of bromocriptine treatment on prolactin, noradrenaline and blood pressure in hypertensive haemodialysis patients. Clin. Sci. 69 (1), 51-56 (1985). (Pubitemid 15032475)
101. Walden RJ, Hernandez J, Bhattacharjee P, Graham B, Prichard BN. Bromocriptine in the treatment of hypertension. Eur. J. Clin. Pharmacol. 30 (2), 141-144 (1986). (Pubitemid 16166058)
102. Reuwer AQ, Twickler MT, Hutten BA et al. Prolactin levels and the risk of future coronary artery disease in apparently healthy men and women. Circ. Cardiovasc. Genet. 2 (4), 389-395 (2009).
103. Corona G, Rastrelli G, Boddi V et al. Prolactin levels independently predictmajor cardiovascular events in patients with erectile dysfunction. Int. J. Androl. 34 (3), 217-224 (2011).
104. Yuan X, Yamada K, Ishiyama-Shigemoto S, Koyama W, Nonaka K. Identification of polymorphic loci in the promoter region of the serotonin 5-HT2C receptor gene and their association with obesity and Type II diabetes. Diabetologia 43 (3), 373-376 (2000). (Pubitemid 30163481)
105. Ricca V, Nacmias B, Cellini E, Di Bernardo M, Rotella CM, Sorbi S. 5-HT2A receptor gene polymorphism and eating disorders. Neurosci. Lett. 323 (2), 105-108 (2002). (Pubitemid 34310251)
106. Rosmond R, Bouchard C, Björntorp P. Increased abdominal obesity in subjects with a mutation in the 5-HT (2A) receptor gene promoter. Ann. NY Acad. Sci. 967, 571-575 (2002). (Pubitemid 34721949)
107. Coto E, Reguero JR, Alvarez V et al. 5-hydroxytryptamine 5-HT2A receptor and 5-hydroxytryptamine transporter polymorphisms in acute myocardial infarction. Clin. Sci. 104 (3), 241-245 (2003). (Pubitemid 36308169)
108. Melkersson K, Berinder K, Hulting AL. Effect of antipsychotic-induced hyperprolactinemia on anthropometric measures, insulin sensitivity and lipid profile in patients with schizophrenia or related psychoses. Neuro Endocrinol. Lett. 32 (4), 428-436 (2011).
109. Stamatelopoulos KS, Georgiopoulos GA, Sfikakis PP et al. Pilot study of circulating prolactin levels and endothelial function in men with hypertension. Am. J. Hypertens. 24 (5), 569-573 (2011).